,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,155,1,1,,86929,750,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad50 strain,Other,,
1,157,1,1,,86929,750,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mec2-1 strain,Other,,
2,161,1,1,,86929,750,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the sgs1 mgt1 strain,Other,,
3,165,1,1,,86929,750,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the cln2 rad14 strain,Other,,
4,167,1,1,,86929,750,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the bub3 strain,Other,,
5,175,1,1,,86929,750,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mlh1 rad18 strain,Other,,
6,230,1,1,,86929,750,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lymphosarcoma Gardner 6C3HED (intraperitoneal) in C3H/He mice,Other,,
7,244,1,1,,86929,750,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lymphoma 8 (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
8,248,1,1,,86929,750,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
9,328,1,1,,86929,750,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
10,330,1,1,,86929,750,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
11,410,1,5,,11113413,750,Inactive,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
12,411,2,1,,11113413,750,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
13,445,3,1,,11113413,750,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
14,447,1,1,,11113413,750,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
15,448,1,2,,11113413,750,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
16,450,1,2,,11113413,750,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
17,451,1,2,,11113413,750,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
18,526,1,1,,11113413,750,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
19,530,1,1,,11113413,750,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
20,584,1,3,,11113413,750,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
21,585,1,4,,11113413,750,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
22,595,1,3,,11113413,750,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
23,596,1,2,,11113413,750,Inconclusive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
24,597,1,3,,11113413,750,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
25,603,1,2,,11113413,750,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
26,605,1,2,,11113413,750,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
27,607,1,3,,11113413,750,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
28,662,1,1,,11113413,750,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
29,875,1,2,,11113413,750,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
30,880,2,1,,11113413,750,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
31,880,2,1,,11113413,750,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
32,881,2,2,,11113413,750,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
33,883,1,3,,11113413,750,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
34,884,1,2,,11113413,750,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
35,885,1,2,,11113413,750,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
36,886,1,2,,11113413,750,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
37,886,1,2,,11113413,750,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
38,887,1,2,,11113413,750,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
39,889,1,3,,11113413,750,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
40,891,1,2,,11113413,750,Inactive,40805836.0,1565.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
41,892,1,2,,11113413,750,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
42,893,1,2,,11113413,750,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
43,893,1,2,,11113413,750,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
44,894,2,1,,11113413,750,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
45,899,1,2,,11113413,750,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
46,900,1,3,,11113413,750,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
47,901,1,2,,11113413,750,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
48,902,1,2,,11113413,750,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
49,912,1,2,,11113413,750,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
50,923,1,2,,11113413,750,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
51,924,1,2,,11113413,750,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
52,926,1,2,,11113413,750,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
53,938,1,2,,11113413,750,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
54,995,1,2,,11113413,750,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
55,1030,2,1,,11113413,750,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
56,1189,1,5,,48413824,750,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results,Other,,
57,1194,1,3,,48413824,750,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Salmonella Mutagenicity,Other,,
58,1195,1,2,,48416066,750,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
59,1208,1,3,,48413824,750,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results,Other,,
60,1379,1,2,,11113413,750,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
61,1452,1,1,,11113413,750,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
62,1454,1,1,,11113413,750,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
63,1457,1,1,,11113413,750,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
64,1460,1,3,,11113413,750,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
65,1463,1,1,,11113413,750,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
66,1467,1,3,,11113413,750,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
67,1468,1,1,,11113413,750,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
68,1469,1,1,,11113413,750,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
69,1469,1,1,,26751653,750,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
70,1471,2,1,,11113413,750,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
71,1476,2,1,,11113413,750,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
72,1477,1,1,,11113413,750,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
73,1477,1,1,,26751653,750,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
74,1478,2,1,,11113413,750,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
75,1479,1,2,,11113413,750,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
76,1479,1,2,,26751653,750,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
77,1490,2,1,,11113413,750,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
78,1490,2,1,,26751653,750,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
79,1519,1,3,,11113413,750,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
80,1766,1,1,,11113413,750,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
81,1766,1,1,,11113413,750,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
82,1766,1,1,,26751653,750,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
83,1766,1,1,,26751653,750,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
84,1768,1,1,,11113413,750,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
85,1768,1,1,,11113413,750,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
86,1768,1,1,,26751653,750,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
87,1768,1,1,,26751653,750,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
88,1851,1,2,,11113413,750,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
89,1851,1,2,1.0,11113413,750,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
90,1851,1,2,2.0,11113413,750,Inactive,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
91,1851,1,2,3.0,11113413,750,Inactive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
92,1851,1,2,4.0,11113413,750,Inactive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
93,1851,1,2,5.0,11113413,750,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
94,1865,1,1,,11113413,750,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
95,1948,1,1,,11113413,750,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
96,2059,1,2,,85209913,750,Active,,,,,Ligands of Class C GPCRs,Other,,
97,2101,1,1,,11113413,750,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
98,2101,1,1,,26751653,750,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
99,2107,1,1,,11113413,750,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
100,2107,1,1,,26751653,750,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
101,2112,1,1,,11113413,750,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
102,2112,1,1,,26751653,750,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
103,2147,1,1,,11113413,750,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
104,2314,1,2,,26751653,750,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
105,2314,1,2,,26751653,750,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
106,2315,1,2,,26751653,750,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
107,2315,1,2,,26751653,750,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
108,2451,1,2,,11113413,750,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
109,2451,1,2,,26751653,750,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
110,2472,1,2,,11113413,750,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
111,2472,1,2,,26751653,750,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
112,2517,2,1,,26751653,750,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
113,2517,2,1,,144207124,750,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
114,2528,1,2,,11113413,750,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
115,2528,1,2,,26751653,750,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
116,2546,1,1,,11113413,750,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
117,2546,1,1,,26751653,750,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
118,2549,1,1,,11113413,750,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
119,2549,1,1,,26751653,750,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
120,2551,1,1,,11113413,750,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
121,2551,1,1,,26751653,750,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
122,23504,4,2,,103204298,750,Unspecified,,,,,Calculated partition coefficient (clogP) (Pomona),Other,2549245.0,
123,26351,4,4,,103204298,750,Unspecified,,,,,pKa value was determined,Other,6818345.0,
124,26797,4,1,,103204298,750,Unspecified,,,,,Partition coefficient (logP),Other,3656360.0,
125,51033,8,2,,103204298,750,Unspecified,,,500.0,EC50,"Concentration required for obtaining 50% of the fluorescence intensity of copper-free calcein 1, in bovine serum albumin",Confirmatory,12729634.0,
126,92041,3,7,,103204298,750,Unspecified,,,,,Percent control measured by evaluating the inhibition of 3 nM [125I]PhTX-343-lysine binding to glutamate receptors in rat cortical membranes,Other,1652018.0,
127,110561,3,3,,103204298,750,Unspecified,,,,,The average latency on the onset of the seizures compared to the controls after 30 min in the strychnine test at a dose of 150 mg/kg,Other,9438018.0,
128,110563,3,3,,103204298,750,Unspecified,,,,,The average latency on the onset of the seizures compared to the controls after 30 min in the strychnine test at a dose of 300 mg/kg,Other,9438018.0,
129,110567,3,3,,103204298,750,Unspecified,,,,,The average latency on the onset of the seizures compared to the controls after 3h in the strychnine test at a dose of 150 mg/kg,Other,9438018.0,
130,110569,3,3,,103204298,750,Unspecified,,,,,The average latency on the onset of the seizures compared to the controls after 3h in the strychnine test at a dose of 300 mg/kg,Other,9438018.0,
131,118601,3,3,,103204298,750,Unspecified,,,,,Ratio of the animals protected to animals tested after 30 min. in the MES test after intraperitoneal administration to mice at a dose of 750 mg/kg; Animals protected / Animals tested = 0/8,Other,9438018.0,
132,118604,3,3,,103204298,750,Unspecified,,,,,Ratio of the animals protected to animals tested after 3h in the MES test after intraperitoneal administration to mice at a dose of 750 mg/kg; Animals protected / Animals tested = 0/8,Other,9438018.0,
133,120086,3,3,,103204298,750,Unspecified,,,,,Percent of the tonic seizures after 30 min in the 3-mercaptopropionic acid test,Other,9438018.0,
134,120090,5,2,,103204298,750,Inconclusive,,,,,Percent of the tonic seizures after 30 min in the 3-mercaptopropionic acid test; Not determined,Other,9438018.0,
135,120091,3,3,,103204298,750,Unspecified,,,,,Percent of the tonic seizures after 3h in the 3-mercaptopropionic acid test,Other,9438018.0,
136,120095,5,2,,103204298,750,Inconclusive,,,,,Percent of the tonic seizures after 3h in the 3-mercaptopropionic acid test; Not determined,Other,9438018.0,
137,143065,9,2,,103204298,750,Active,,,0.25,IC50,In vitro inhibitory activity to inhibit [3H]glycine binding to NMDA receptor,Confirmatory,10360746.0,
138,143072,9,1,,103204298,750,Active,,,0.086,IC50,"Tested for binding affinity against NMDA receptor, from rat synaptic membrane, using [3H]glycine as the radioligand.",Confirmatory,8093907.0,
139,143084,7,1,,103204298,750,Active,,,0.17,Ki,"Affinity for the glycine binding site of NMDA receptor by inhibition of [3H]5,7-dichlorokynurenic acid ([3H]DCKA) binding to rat brain synaptic membrane",Confirmatory,7966156.0,
140,143467,8,2,,103204298,750,Active,,,6.0,IC50,Inhibition of binding of [3H]strychnine to glycine receptor in rat,Confirmatory,2549245.0,
141,143614,9,2,,103204298,750,Active,,,6.2,IC50,Inhibitory concentration required to inhibit [3H]strychnine binding to N-methyl-D-aspartate glutamate receptor 1,Confirmatory,1310117.0,
142,144598,9,1,,103204298,750,Active,,,0.69,IC50,Binding affinity against glycine binding site associated with N-methyl-D-aspartate glutamate receptor of rat synaptic plasma membrane(SPM) determined using [3H]glycine as radioligand.,Confirmatory,1433216.0,
143,144825,9,2,,103204298,750,Active,,,0.2,EC50,Compound was evaluated for in vitro inhibition of [3H]TCP at NMDA receptor,Confirmatory,7990104.0,
144,145252,6,2,,103204298,750,Active,,,0.068,EC50,In vitro concentration eliciting half-maximal effect on [3H]-MK 801 radioligand binding to NMDA receptor,Confirmatory,10360746.0,
145,145253,3,3,,103204298,750,Unspecified,,,,,In vitro maximal effect on [3H]-MK 801 binding to NMDA receptor as compared to a basal value of 100%,Other,10360746.0,
146,145260,9,2,,103204298,750,Active,,,0.2,IC50,In vitro inhibition of [3H]glycine at NMDA receptor,Confirmatory,7990104.0,
147,146058,6,2,,103204298,750,Active,,,0.84,EC50,Effective concentration against NR1/NR2A receptor,Confirmatory,10893301.0,
148,146060,6,2,,103204298,750,Active,,,0.19,EC50,Effective concentration against NR1/NR2B receptor,Confirmatory,10893301.0,
149,146062,6,2,,103204298,750,Active,,,0.15,EC50,Effective concentration against NR1/NR2C receptor,Confirmatory,10893301.0,
150,146064,6,2,,103204298,750,Active,,,0.096,EC50,Effective concentration against NR1/NR2D receptor,Confirmatory,10893301.0,
151,198301,3,4,,103204298,750,Unspecified,,,,,"Cleavage rate against hairpin ribozyme at 2 mM, in presence of 0.5 uM magnesium ions",Other,11714598.0,
152,198302,3,3,,103204298,750,Unspecified,,,,,Cleavage rate against hairpin ribozyme at 5 mM with 0.5 uM magnesium ions,Other,11714598.0,
153,233320,3,3,,103204298,750,Unspecified,,,,,Bitter threshold value; NB denotes 'Not bitter',Other,3656360.0,
154,266246,7,6,,103204298,750,Inconclusive,1172435.0,6564.0,,EC50,Activation of human PEPT1 expressed in MDCK cells,Confirmatory,16759105.0,
155,266247,4,10,,103204298,750,Inactive,1172435.0,6564.0,,,Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar,Other,16759105.0,
156,266248,3,9,,103204298,750,Inconclusive,1172435.0,6564.0,,,Ratio of %GSmax to EC50 for human PEPT1 activation,Other,16759105.0,
157,266249,7,6,,103204298,750,Inconclusive,1172435.0,6564.0,,IC50,Binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells,Confirmatory,16759105.0,
158,270051,8,2,,103204298,750,Active,,,15.8,IC50,Displacement of [3H]strychnine from strychnine-sensitive glycine receptor in rat spinal cord,Confirmatory,16942030.0,
159,286349,6,3,,103204298,750,Active,,,15.8,IC50,Displacement of [3H]strychnine from glycine receptor in rat spinal cord synaptosomal membranes,Confirmatory,17411024.0,
160,297967,10,2,,103204298,750,Inconclusive,2506127.0,1139.0,,IC50,Antagonist activity at human alpha-7 nAChR in tsA201 cells coexpressed with Ric3 by FMP assay,Confirmatory,17722904.0,
161,297968,9,1,,103204298,750,Inconclusive,,,,IC50,Antagonist activity at rat alpha3beta4 nAChR expressed in HEK293 cells by FMP assay,Confirmatory,17722904.0,
162,297969,10,2,,103204298,750,Inconclusive,1168222.0,3359.0,,IC50,Antagonist activity at human 5HT3A receptor expressed in HEK293 cells by FMP assay,Confirmatory,17722904.0,
163,297970,9,1,,103204298,750,Inconclusive,,,,IC50,Antagonist activity at human rho1 GABAc receptor in HEK293 cells by FMP assay,Confirmatory,17722904.0,
164,297971,10,2,,103204298,750,Unspecified,116242495.0,2741.0,,IC50,Antagonist activity at human glycine alpha-1 receptor in HEK293 cells by FMP assay,Confirmatory,17722904.0,
165,430782,5,3,,103204298,750,Active,,,0.12589,Ki,Displacement of [3H]glycine from strychnine-insensitive glycine recognition site of NMDA receptor in rat brain cortex membrane,Confirmatory,19642674.0,
166,443653,3,3,,103204298,750,Active,,,,,Binding affinity to 30 mM pyridoxal-5'-phosphate assessed as formation of PLP-aldimine by ESI-MS analysis,Other,19791805.0,
167,476929,3,3,,103204298,750,Unspecified,,,,,Human intestinal absorption in po dosed human,Other,20022146.0,
168,485281,1,1,,26751653,750,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
169,485290,1,1,,11113413,750,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
170,485290,1,1,,26751653,750,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
171,504327,1,1,,11113413,750,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
172,504327,1,1,,26751653,750,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
173,504845,1,1,,11113413,750,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
174,504847,1,1,,11113413,750,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
175,504847,1,1,,26751653,750,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
176,504865,1,1,,11113413,750,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
177,517590,1,3,,103204298,750,Unspecified,,,,,"Analgesic activity in mouse assessed as pain threshold variation at 30 umol/kg, po after 30 mins (RVb = 0.13 +/- 0.14 %)",Other,20833035.0,
178,517594,1,3,,103204298,750,Unspecified,,,,,"Analgesic activity in mouse assessed as pain threshold variation at 30 umol/kg, po after 60 mins (RVb = 0.15 +/- 0.16 %)",Other,20833035.0,
179,517597,1,3,,103204298,750,Unspecified,,,,,"Analgesic activity in mouse assessed as pain threshold variation at 30 umol/kg, po after 90 mins (RVb = 0.17 +/- 0.14 %)",Other,20833035.0,
180,517600,1,3,,103204298,750,Unspecified,,,,,"Analgesic activity in mouse assessed as pain threshold variation at 30 umol/kg, po after 120 mins (RVb = 0.18 +/- 0.15 %)",Other,20833035.0,
181,517603,1,3,,103204298,750,Unspecified,,,,,"Analgesic activity in mouse assessed as pain threshold variation at 30 umol/kg, po after 150 mins (RVb = 0.16 +/- 0.13 %)",Other,20833035.0,
182,517606,1,3,,103204298,750,Unspecified,,,,,"Analgesic activity in mouse assessed as pain threshold variation at 30 umol/kg, po after 180 mins (RVb = 0.15 +/- 0.12 %)",Other,20833035.0,
183,566258,2,4,,103204298,750,Active,,,0.223,IC50,Inhibition of rat glutamate receptor,Confirmatory,20875743.0,
184,588211,2,3,,103204298,750,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
185,588212,2,3,,103204298,750,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
186,588213,2,3,,103204298,750,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
187,588220,2,3,,103204298,750,Unspecified,,,,,Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset,Other,20020916.0,
188,588379,1,2,,11113413,750,Inactive,13399304.0,60489.0,,Potency,qHTS for inhibitors of Vif-A3G interactions: Validation,Confirmatory,,
189,588579,1,1,,11113413,750,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
190,588579,1,1,,26751653,750,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
191,595474,8,2,,103204298,750,Unspecified,400623.0,14412.0,2238.72,IC50,Inhibition of mouse GAT2-mediated [3H]GABA uptake expressed in human HEK cells,Confirmatory,21353350.0,
192,595475,8,2,,103204298,750,Unspecified,341942004.0,243616.0,1348.96,IC50,Inhibition of mouse GAT3-mediated [3H]GABA uptake expressed in human HEK cells,Confirmatory,21353350.0,
193,595476,5,1,,103204298,750,Unspecified,,,3090.3,IC50,Inhibition of mouse GAT4-mediated [3H]GABA uptake expressed in human HEK cells,Confirmatory,21353350.0,
194,595481,1,10,,103204298,750,Unspecified,47117844.0,232333.0,,,Inhibition of mouse GAT1-mediated [3H]GABA uptake expressed in human HEK cells assessed as specific binding remaining at 10 mM,Other,21353350.0,
195,602332,1,1,,11113413,750,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
196,602332,1,1,,26751653,750,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
197,624030,1,2,,11113413,750,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
198,624170,1,1,,11113413,750,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
199,624172,1,1,,11113413,750,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
200,624173,1,3,,11113413,750,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
201,625144,5,5,,103204298,750,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
202,625145,4,7,,103204298,750,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
203,625146,5,5,,103204298,750,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
204,625147,4,7,,103204298,750,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
205,625148,4,7,,103204298,750,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
206,625149,4,7,,103204298,750,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
207,625150,5,5,,103204298,750,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
208,625151,4,7,,103204298,750,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
209,625152,4,7,,103204298,750,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
210,625153,4,7,,103204298,750,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
211,625154,4,7,,103204298,750,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
212,625155,4,7,,103204298,750,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
213,625156,1,9,,103204298,750,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
214,625157,6,2,,103204298,750,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
215,625158,3,4,,103204298,750,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
216,625159,5,5,,103204298,750,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
217,625160,1,9,,103204298,750,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
218,625161,4,7,,103204298,750,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
219,625162,4,7,,103204298,750,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
220,625163,4,7,,103204298,750,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
221,625164,1,6,,103204298,750,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
222,625165,3,4,,103204298,750,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
223,625166,3,4,,103204298,750,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
224,625167,5,5,,103204298,750,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
225,625168,4,7,,103204298,750,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
226,625169,1,6,,103204298,750,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
227,625170,3,4,,103204298,750,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
228,625171,4,7,,103204298,750,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
229,625172,4,7,,103204298,750,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
230,625173,5,5,,103204298,750,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
231,625174,5,5,,103204298,750,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
232,625175,5,5,,103204298,750,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
233,625176,1,9,,103204298,750,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
234,625177,5,5,,103204298,750,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
235,625178,5,5,,103204298,750,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
236,625179,1,9,,103204298,750,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
237,625180,5,5,,103204298,750,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
238,625181,5,5,,103204298,750,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
239,625182,5,5,,103204298,750,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
240,625183,5,5,,103204298,750,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
241,625184,5,5,,103204298,750,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
242,625185,5,5,,103204298,750,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
243,625186,5,5,,103204298,750,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
244,625187,5,5,,103204298,750,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
245,625188,1,9,,103204298,750,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
246,625189,1,7,,103204298,750,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
247,625190,4,5,,103204298,750,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
248,625191,4,7,,103204298,750,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
249,625192,4,7,,103204298,750,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
250,625193,5,5,,103204298,750,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
251,625194,4,7,,103204298,750,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
252,625195,4,7,,103204298,750,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
253,625196,5,6,,103204298,750,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
254,625197,3,4,,103204298,750,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
255,625198,4,7,,103204298,750,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
256,625199,4,7,,103204298,750,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
257,625200,4,7,,103204298,750,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
258,625201,4,7,,103204298,750,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
259,625202,4,7,,103204298,750,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
260,625203,4,7,,103204298,750,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
261,625204,4,7,,103204298,750,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
262,625205,4,7,,103204298,750,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
263,625206,4,7,,103204298,750,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
264,625207,4,7,,103204298,750,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
265,625208,5,5,,103204298,750,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
266,625209,4,7,,103204298,750,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
267,625210,3,4,,103204298,750,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
268,625211,1,6,,103204298,750,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
269,625212,3,4,,103204298,750,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
270,625213,4,7,,103204298,750,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
271,625214,1,9,,103204298,750,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
272,625215,3,4,,103204298,750,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
273,625216,3,4,,103204298,750,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
274,625217,4,7,,103204298,750,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
275,625218,4,7,,103204298,750,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
276,625219,3,4,,103204298,750,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
277,625220,4,7,,103204298,750,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
278,625221,4,7,,103204298,750,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
279,625222,4,7,,103204298,750,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
280,625223,4,7,,103204298,750,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
281,625224,3,4,,103204298,750,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
282,625225,3,4,,103204298,750,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
283,625226,4,7,,103204298,750,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
284,625227,4,7,,103204298,750,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
285,625228,4,7,,103204298,750,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
286,625229,5,5,,103204298,750,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
287,625230,1,6,,103204298,750,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
288,625231,4,7,,103204298,750,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
289,625232,1,9,,103204298,750,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
290,625233,4,7,,103204298,750,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
291,625234,3,4,,103204298,750,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
292,625235,4,7,,103204298,750,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
293,625236,5,5,,103204298,750,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
294,625237,4,7,,103204298,750,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
295,625238,4,7,,103204298,750,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
296,625239,4,7,,103204298,750,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
297,625240,1,9,,103204298,750,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
298,625241,4,7,,103204298,750,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
299,625242,4,7,,103204298,750,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
300,625243,5,5,,103204298,750,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
301,625244,5,5,,103204298,750,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
302,625245,5,5,,103204298,750,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
303,625246,1,9,,103204298,750,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
304,625247,5,5,,103204298,750,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
305,625248,5,5,,103204298,750,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
306,625249,5,5,,103204298,750,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
307,625250,5,5,,103204298,750,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
308,625251,5,5,,103204298,750,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
309,625252,4,7,,103204298,750,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
310,625253,4,7,,103204298,750,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
311,625254,4,7,,103204298,750,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
312,625255,4,7,,103204298,750,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
313,625256,4,7,,103204298,750,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
314,625257,4,7,,103204298,750,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
315,625258,4,7,,103204298,750,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
316,625259,4,7,,103204298,750,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
317,625260,3,4,,103204298,750,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
318,625261,3,4,,103204298,750,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
319,625262,3,4,,103204298,750,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
320,625263,4,7,,103204298,750,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
321,625264,3,4,,103204298,750,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
322,625265,1,6,,103204298,750,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
323,625266,3,4,,103204298,750,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
324,625267,3,4,,103204298,750,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
325,625268,4,2,,103204298,750,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
326,625268,4,2,,103204298,750,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
327,625268,4,2,,103204298,750,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
328,625268,4,2,,103204298,750,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
329,625269,4,7,,103204298,750,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
330,625270,4,7,,103204298,750,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
331,625271,5,5,,103204298,750,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
332,625272,3,4,,103204298,750,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
333,625273,4,6,,103204298,750,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
334,625274,1,6,,103204298,750,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
335,625275,3,4,,103204298,750,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
336,625279,1,3,,103204298,750,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
337,625280,1,3,,103204298,750,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
338,625281,1,3,,103204298,750,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
339,625282,1,3,,103204298,750,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
340,625283,1,3,,103204298,750,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
341,625284,1,3,,103204298,750,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
342,625285,1,3,,103204298,750,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
343,625286,1,3,,103204298,750,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
344,625287,1,3,,103204298,750,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
345,625288,1,3,,103204298,750,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
346,625289,1,3,,103204298,750,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
347,625290,1,3,,103204298,750,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
348,625291,1,3,,103204298,750,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
349,625292,1,3,,103204298,750,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
350,630741,4,6,,103204298,750,Unspecified,51316800.0,206358.0,,Ki,Inhibition of human PAT1-mediated L-[3H]proline uptake in human Caco2 cells after 10 mins by liquid scintillation counting,Confirmatory,21955456.0,
351,631077,1,9,,103204298,750,Unspecified,47117844.0,232333.0,,,Inhibition of mouse GAT1-mediated [3H]GABA uptake expressed in human HEK cells at 1 mM,Other,21940173.0,
352,631078,1,9,,103204298,750,Unspecified,400623.0,14412.0,,,Inhibition of mouse GAT2-mediated [3H]GABA uptake expressed in human HEK cells at 1 mM,Other,21940173.0,
353,631079,1,9,,103204298,750,Unspecified,341942004.0,243616.0,,,Inhibition of mouse GAT3-mediated [3H]GABA uptake expressed in human HEK cells at 1 mM,Other,21940173.0,
354,631080,1,9,,103204298,750,Unspecified,341942004.0,243616.0,,,Inhibition of mouse GAT4-mediated [3H]GABA uptake expressed in human HEK cells at 1 mM,Other,21940173.0,
355,651631,4,1,,144207124,750,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
356,651632,4,1,,144207124,750,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
357,651633,4,1,,144207124,750,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
358,651634,4,1,,144207124,750,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
359,652048,1,2,,144207124,750,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
360,652051,1,1,,144207124,750,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
361,678712,1,8,,103204298,750,Active,117144.0,1544.0,,,Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins,Other,22931300.0,
362,678713,1,8,,103204298,750,Active,6686268.0,1559.0,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Other,22931300.0,
363,678714,1,8,,103204298,750,Active,60416369.0,1557.0,,,Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
364,678715,1,8,,103204298,750,Active,84028191.0,1565.0,,,Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
365,678716,1,8,,103204298,750,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins,Other,22931300.0,
366,678717,1,8,,103204298,750,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins,Other,22931300.0,
367,678722,1,5,,103204298,750,Inconclusive,,,,,Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH,Other,22931300.0,
368,681113,3,6,,103204298,750,Unspecified,81871541.0,170566.0,,Ki,TP_TRANSPORTER: inhibition of L-tryptophan uptake in Xenopus laevis oocytes,Confirmatory,11278508.0,
369,681145,2,7,,103204298,750,Unspecified,121945115.0,,,Km,TP_TRANSPORTER: uptake in Xenopus laevis oocytes,Confirmatory,11827462.0,
370,686978,1,1,,144207124,750,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
371,686979,1,1,,144207124,750,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
372,695510,1,2,,103204298,750,Inactive,,,,,Vasodilatory activity in Wistar rat RASMC cells assessed as increase in cGMP levels at 100 uM after 5 mins by enzyme immunoassay relative to control,Other,22436388.0,
373,695876,2,3,,103204298,750,Unspecified,,,50000.0,IC50,Cytotoxicity against drug-resistant human KBV1 cells expressing P-gp incubated for 72 hrs by MTT assay,Confirmatory,21657271.0,
374,695877,2,3,,103204298,750,Unspecified,,,50000.0,IC50,Cytotoxicity against human KB-3-1 cells incubated for 72 hrs by MTT assay,Confirmatory,21657271.0,
375,720516,2,1,,144207124,750,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
376,720532,1,1,,26751653,750,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
377,720532,1,1,,144207124,750,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
378,720533,1,1,,26751653,750,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
379,720533,1,1,,144207124,750,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
380,720552,2,1,,144207124,750,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
381,720634,2,1,,144207124,750,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
382,720635,2,1,,144207124,750,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
383,720637,2,1,,144207124,750,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
384,720674,2,2,,144207124,750,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
385,720675,2,2,,144207124,750,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
386,720678,2,1,,144207124,750,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
387,720679,2,1,,144207124,750,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
388,720680,2,1,,144207124,750,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
389,720681,2,1,,144207124,750,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
390,720682,2,1,,144207124,750,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
391,720683,2,1,,144207124,750,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
392,720684,2,1,,144207124,750,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
393,720685,2,1,,144207124,750,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
394,720686,2,1,,144207124,750,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
395,720687,2,2,,144207124,750,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
396,720691,4,1,,144207124,750,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
397,720692,3,1,,144207124,750,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
398,720693,3,1,,144207124,750,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
399,720719,2,1,,144207124,750,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
400,720725,2,1,,144207124,750,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
401,733539,1,6,,103204298,750,Inactive,112817.0,25187.0,,,Displacement of [125I]-N-(p-I-Bn)-THAZ from 5HT2C in rat cerebral cortex membrane at 1 mM after 1 hr by scintillation counting analysis,Other,23301527.0,
402,743012,3,1,,144207124,750,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
403,743014,3,1,,144207124,750,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
404,743015,3,1,,144207124,750,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
405,743033,3,1,,144207124,750,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
406,743035,2,1,,144207124,750,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
407,743036,2,1,,144207124,750,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
408,743040,3,1,,144207124,750,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
409,743041,3,1,,144207124,750,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
410,743042,3,1,,144207124,750,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
411,743053,2,1,,144207124,750,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
412,743054,2,1,,144207124,750,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
413,743063,2,1,,144207124,750,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
414,743064,3,1,,144207124,750,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
415,743065,3,1,,144207124,750,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
416,743066,3,1,,144207124,750,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
417,743067,2,1,,144207124,750,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
418,743069,2,1,,144207124,750,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
419,743074,2,1,,144207124,750,Inconclusive,,,8.4852,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
420,743075,2,1,,144207124,750,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
421,743077,2,1,,144207124,750,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
422,743078,2,1,,144207124,750,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
423,743079,3,1,,144207124,750,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
424,743080,3,1,,144207124,750,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
425,743081,3,1,,144207124,750,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
426,743083,3,1,,144207124,750,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
427,743084,3,1,,144207124,750,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
428,743085,3,1,,144207124,750,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
429,743086,3,1,,144207124,750,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
430,743091,2,1,,144207124,750,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
431,743094,3,1,,144207124,750,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
432,743122,2,1,,144207124,750,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
433,743139,2,1,,144207124,750,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
434,743140,2,1,,144207124,750,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
435,743191,3,1,,170466831,750,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
436,743194,3,1,,170466831,750,Inconclusive,,,5.1721,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
437,743199,2,1,,170466831,750,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
438,743202,4,1,,170466831,750,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
439,743203,3,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
440,743209,3,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
441,743210,4,1,,170466831,750,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
442,743211,3,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
443,743212,3,1,,170466831,750,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
444,743213,3,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
445,743215,3,1,,170466831,750,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
446,743217,3,1,,170466831,750,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
447,743218,3,1,,170466831,750,Inconclusive,,,0.0008,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
448,743219,3,1,,170466831,750,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
449,743220,3,1,,170466831,750,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
450,743221,3,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
451,743222,3,1,,170466831,750,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
452,743223,3,1,,170466831,750,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
453,743224,3,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
454,743225,3,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
455,743226,2,1,,170466831,750,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
456,743227,2,1,,170466831,750,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
457,743228,3,1,,170466831,750,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
458,743239,2,1,,170466831,750,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
459,743240,2,1,,170466831,750,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
460,743241,2,1,,170466831,750,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
461,743242,2,1,,170466831,750,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
462,743244,1,1,,144207124,750,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
463,781327,1,2,,103204298,750,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Morgenthaler ref: ChemMedChem 2007,Other,24249037.0,
464,934441,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R020730,Other,,
465,934442,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R020730,Other,,
466,934443,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R020730,Other,,
467,935072,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R020730,Other,,
468,935073,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R020730,Other,,
469,935074,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R020730,Other,,
470,935075,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R020730,Other,,
471,935076,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R020730,Other,,
472,935077,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R020730,Other,,
473,935078,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R020730,Other,,
474,935079,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R020730,Other,,
475,935080,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R020730,Other,,
476,935081,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R020730,Other,,
477,948831,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R020730,Other,,
478,949342,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R020730,Other,,
479,949343,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R020730,Other,,
480,949344,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R020730,Other,,
481,949345,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R020730,Other,,
482,949346,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R020730,Other,,
483,949347,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R020730,Other,,
484,949348,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R020730,Other,,
485,949349,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R020730,Other,,
486,949350,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R020730,Other,,
487,949351,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R020730,Other,,
488,949352,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R020730,Other,,
489,949353,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R020730,Other,,
490,960568,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R020730,Other,,
491,960569,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R020730,Other,,
492,960570,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R020730,Other,,
493,960571,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R020730,Other,,
494,960572,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R020730,Other,,
495,960573,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R020730,Other,,
496,960574,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R020730,Other,,
497,960575,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R020730,Other,,
498,960576,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R020730,Other,,
499,960577,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R020730,Other,,
500,960578,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R020730,Other,,
501,960579,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R020730,Other,,
502,960580,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R020730,Other,,
503,960581,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R020730,Other,,
504,960582,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R020730,Other,,
505,963374,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R020730,Other,,
506,963375,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R020730,Other,,
507,963376,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R020730,Other,,
508,963377,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R020730,Other,,
509,963378,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R020730,Other,,
510,963379,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R020730,Other,,
511,963380,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R020730,Other,,
512,963381,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R020730,Other,,
513,963382,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R020730,Other,,
514,963383,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R020730,Other,,
515,963806,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R020730,Other,,
516,963807,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R020730,Other,,
517,963808,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R020730,Other,,
518,963809,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R020730,Other,,
519,963810,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R020730,Other,,
520,1033445,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: R020730,Other,,
521,1033446,1,3,,103204298,750,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: R020730",Other,,
522,1033447,1,3,,103204298,750,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: R020730",Other,,
523,1033448,1,3,,103204298,750,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: R020730",Other,,
524,1033449,1,3,,103204298,750,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: R020730",Other,,
525,1033450,1,3,,103204298,750,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: R020730",Other,,
526,1033451,1,3,,103204298,750,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: R020730,Other,,
527,1033452,1,3,,103204298,750,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: R020730",Other,,
528,1034033,1,3,,103204298,750,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: R020730",Other,,
529,1034034,1,3,,103204298,750,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: R020730",Other,,
530,1034035,1,3,,103204298,750,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: R020730",Other,,
531,1034036,1,3,,103204298,750,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: R020730",Other,,
532,1034037,1,3,,103204298,750,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: R020730",Other,,
533,1034038,1,3,,103204298,750,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: R020730",Other,,
534,1034039,1,3,,103204298,750,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: R020730",Other,,
535,1034040,1,3,,103204298,750,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: R020730",Other,,
536,1034041,1,3,,103204298,750,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: R020730",Other,,
537,1034042,1,3,,103204298,750,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: R020730",Other,,
538,1034043,1,3,,103204298,750,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: R020730",Other,,
539,1034044,1,3,,103204298,750,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: R020730",Other,,
540,1034045,1,3,,103204298,750,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: R020730",Other,,
541,1034046,1,3,,103204298,750,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: R020730",Other,,
542,1034047,1,3,,103204298,750,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: R020730",Other,,
543,1034048,1,3,,103204298,750,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: R020730",Other,,
544,1034049,1,3,,103204298,750,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: R020730",Other,,
545,1070046,4,2,,103204298,750,Active,302393807.0,6536.0,31.6,IC50,Inhibition of GlyT1 (unknown origin) assessed as inhibition of [14C]glycine uptake,Confirmatory,24461352.0,
546,1117298,1,2,,170466831,750,Inactive,,,1.2589,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
547,1117304,1,2,,170466831,750,Inactive,,,4.4668,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
548,1117305,1,2,,170466831,750,Inactive,,,2.8184,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
549,1117310,1,1,,170466831,750,Inactive,,,1.2589299999999999,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
550,1117312,1,1,,170466831,750,Inactive,,,2.81838,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
551,1117314,1,1,,170466831,750,Inactive,,,4.46684,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
552,1117326,1,1,,170466831,750,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
553,1117329,1,1,,170466831,750,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
554,1117336,1,1,,170466831,750,Inactive,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
555,1117340,1,1,,170466831,750,Inactive,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
556,1117341,1,1,,170466831,750,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
557,1117342,1,1,,170466831,750,Inactive,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
558,1117343,1,1,,170466831,750,Inactive,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
559,1117346,1,1,,170466831,750,Inactive,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
560,1159509,1,1,,170466831,750,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
561,1159515,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
562,1159516,1,1,,170466831,750,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
563,1159517,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
564,1159518,1,1,,170466831,750,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
565,1159519,1,1,,170466831,750,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
566,1159520,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
567,1159521,1,1,,170466831,750,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
568,1159523,1,1,,170466831,750,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
569,1159524,1,1,,144207124,750,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
570,1159525,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
571,1159526,1,1,,170466831,750,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
572,1159527,1,1,,170466831,750,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
573,1159528,1,1,,170466831,750,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
574,1159529,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
575,1159531,1,1,,170466831,750,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
576,1159551,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
577,1159552,1,1,,170466831,750,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
578,1159553,2,1,,170466831,750,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
579,1159555,1,1,,170466831,750,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
580,1159614,1,2,,170466831,750,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
581,1159620,1,1,,103204298,750,Active,,,,,Summary of drug indications.,Other,,
582,1185880,1,2,,103204298,750,Unspecified,20139924.0,63826.0,366.0,Ki,Binding affinity to serine recemase (unknown origin),Confirmatory,25066953.0,
583,1224834,3,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
584,1224835,1,1,,170466831,750,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
585,1224836,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
586,1224837,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
587,1224838,1,1,,170466831,750,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
588,1224839,1,1,,170466831,750,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
589,1224840,3,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
590,1224841,3,1,,170466831,750,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
591,1224842,3,1,,170466831,750,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
592,1224843,1,1,,170466831,750,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
593,1224844,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
594,1224845,1,1,,170466831,750,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
595,1224846,1,1,,170466831,750,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
596,1224847,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
597,1224848,3,1,,170466831,750,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
598,1224849,3,1,,170466831,750,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
599,1224857,2,1,,170466831,750,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
600,1224859,2,1,,170466831,750,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
601,1224867,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
602,1224868,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
603,1224869,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
604,1224870,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
605,1224871,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
606,1224872,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
607,1224873,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
608,1224874,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
609,1224875,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
610,1224876,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
611,1224877,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
612,1224878,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
613,1224879,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
614,1224880,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
615,1224881,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
616,1224882,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
617,1224883,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
618,1224884,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
619,1224885,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
620,1224886,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
621,1224887,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
622,1224888,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
623,1224889,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
624,1224890,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
625,1224892,1,1,,170466831,750,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
626,1224893,1,1,,170466831,750,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
627,1224894,1,1,,170466831,750,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
628,1224895,1,1,,170466831,750,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
629,1224896,1,1,,170466831,750,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
630,1259241,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
631,1259242,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
632,1259243,1,1,,170466831,750,Inactive,124375976.0,367.0,14.575,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
633,1259244,1,1,,170466831,750,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
634,1259247,1,1,,170466831,750,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
635,1259248,1,1,,170466831,750,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
636,1259310,1,1,,333471793,750,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
637,1259344,1,1,,144207124,750,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
638,1259364,1,1,,170466831,750,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
639,1259365,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
640,1259366,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
641,1259367,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
642,1259368,1,1,,170466831,750,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
643,1259369,1,1,,170466831,750,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
644,1259377,1,1,,170466831,750,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
645,1259378,1,1,,170466831,750,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
646,1259379,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
647,1259380,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
648,1259381,1,1,,170466831,750,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
649,1259382,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
650,1259383,1,1,,170466831,750,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
651,1259384,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
652,1259385,1,1,,170466831,750,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
653,1259386,1,1,,170466831,750,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
654,1259387,1,1,,170466831,750,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
655,1259388,1,1,,170466831,750,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
656,1259390,1,1,,170466831,750,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
657,1259391,1,1,,170466831,750,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
658,1259392,1,1,,170466831,750,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
659,1259393,1,1,,170466831,750,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
660,1259394,1,1,,170466831,750,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
661,1259395,1,1,,170466831,750,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
662,1259396,1,1,,170466831,750,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
663,1259400,1,1,,170466831,750,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
664,1259401,1,1,,170466831,750,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
665,1259402,1,1,,170466831,750,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
666,1259403,1,1,,170466831,750,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
667,1259404,1,1,,170466831,750,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
668,1259407,1,1,,363903865,750,Inactive,,,,,CCRIS mutagenicity studies,Other,,
669,1259411,1,1,,363903865,750,Inactive,,,,,CCRIS carcinogenicity studies,Other,,
670,1259416,1,2,,340083826,750,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
671,1259421,1,1,,340083826,750,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
